We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » European Regulators Release Final Guidance on Insulin Biosimilars
European Regulators Release Final Guidance on Insulin Biosimilars
Manufacturers of biosimilar insulin-containing products must demonstrate pharmacodynamic and pharmacokinetic similarity profiles to prove similar efficacy to their reference insulin, the European Medicines Agency says in final guidance issued last month.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor